245 related articles for article (PubMed ID: 27845263)
1. Osteoclastogenic capacity of peripheral blood mononuclear cells is not different between women with and without osteoporosis.
Koek WNH; van der Eerden BCJ; Alves RDAM; van Driel M; Schreuders-Koedam M; Zillikens MC; van Leeuwen JPTM
Bone; 2017 Feb; 95():108-114. PubMed ID: 27845263
[TBL] [Abstract][Full Text] [Related]
2. The increased in vitro osteoclastogenesis in patients with rheumatoid arthritis is due to increased percentage of precursors and decreased apoptosis - the In Vitro Osteoclast Differentiation in Arthritis (IODA) study.
Durand M; Boire G; Komarova SV; Dixon SJ; Sims SM; Harrison RE; Nabavi N; Maria O; Manolson MF; Mizianty M; Kurgan L; de Brum-Fernandes AJ
Bone; 2011 Mar; 48(3):588-96. PubMed ID: 20959150
[TBL] [Abstract][Full Text] [Related]
3. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
Seibel MJ; Naganathan V; Barton I; Grauer A
J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
[TBL] [Abstract][Full Text] [Related]
4. Spontaneous osteoclastogenesis: Hypothesis for gender-unrelated osteoporosis screening and diagnosis.
Salamanna F; Giardino R; Fini M
Med Hypotheses; 2017 Nov; 109():70-72. PubMed ID: 29150298
[TBL] [Abstract][Full Text] [Related]
5. MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation.
Li K; Chen S; Cai P; Chen K; Li L; Yang X; Yi J; Luo X; Du Y; Zheng H
Mol Cell Probes; 2020 Feb; 49():101479. PubMed ID: 31706013
[TBL] [Abstract][Full Text] [Related]
6. Osteoclast formation from circulating precursors in osteoporosis.
Jevon M; Hirayama T; Brown MA; Wass JA; Sabokbar A; Ostelere S; Athenasou NA
Scand J Rheumatol; 2003; 32(2):95-100. PubMed ID: 12737328
[TBL] [Abstract][Full Text] [Related]
7. Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women.
D'Amelio P; Grimaldi A; Di Bella S; Tamone C; Brianza SZ; Ravazzoli MG; Bernabei P; Cristofaro MA; Pescarmona GP; Isaia G
J Bone Miner Res; 2008 Mar; 23(3):373-9. PubMed ID: 17967134
[TBL] [Abstract][Full Text] [Related]
8. Strontium substitution in apatitic CaP cements effectively attenuates osteoclastic resorption but does not inhibit osteoclastogenesis.
Schumacher M; Wagner AS; Kokesch-Himmelreich J; Bernhardt A; Rohnke M; Wenisch S; Gelinsky M
Acta Biomater; 2016 Jun; 37():184-94. PubMed ID: 27084107
[TBL] [Abstract][Full Text] [Related]
9. A Simple Pit Assay Protocol to Visualize and Quantify Osteoclastic Resorption In Vitro.
Cen W; Reinert S; Avci-Adali M; Alexander D; Umrath F
J Vis Exp; 2022 Jun; (184):. PubMed ID: 35786686
[TBL] [Abstract][Full Text] [Related]
10. Disease status in autosomal dominant osteopetrosis type 2 is determined by osteoclastic properties.
Chu K; Snyder R; Econs MJ
J Bone Miner Res; 2006 Jul; 21(7):1089-97. PubMed ID: 16813529
[TBL] [Abstract][Full Text] [Related]
11. Osteoclastic metabolism of 25(OH)-vitamin D3: a potential mechanism for optimization of bone resorption.
Kogawa M; Findlay DM; Anderson PH; Ormsby R; Vincent C; Morris HA; Atkins GJ
Endocrinology; 2010 Oct; 151(10):4613-25. PubMed ID: 20739402
[TBL] [Abstract][Full Text] [Related]
12. Increased osteoclast formation and activity by peripheral blood mononuclear cells in chronic liver disease patients with osteopenia.
Olivier BJ; Schoenmaker T; Mebius RE; Everts V; Mulder CJ; van Nieuwkerk KM; de Vries TJ; van der Merwe SW
Hepatology; 2008 Jan; 47(1):259-67. PubMed ID: 18022900
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
14. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
15. Inflammation induces osteoclast differentiation from peripheral mononuclear cells in chronic kidney disease patients: crosstalk between the immune and bone systems.
Cafiero C; Gigante M; Brunetti G; Simone S; Chaoul N; Oranger A; Ranieri E; Colucci S; Pertosa GB; Grano M; Gesualdo L
Nephrol Dial Transplant; 2018 Jan; 33(1):65-75. PubMed ID: 28992140
[TBL] [Abstract][Full Text] [Related]
16. Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio.
Kiviranta R; Morko J; Alatalo SL; NicAmhlaoibh R; Risteli J; Laitala-Leinonen T; Vuorio E
Bone; 2005 Jan; 36(1):159-72. PubMed ID: 15664014
[TBL] [Abstract][Full Text] [Related]
17. Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study.
Durand M; Komarova SV; Bhargava A; Trebec-Reynolds DP; Li K; Fiorino C; Maria O; Nabavi N; Manolson MF; Harrison RE; Dixon SJ; Sims SM; Mizianty MJ; Kurgan L; Haroun S; Boire G; de Fatima Lucena-Fernandes M; de Brum-Fernandes AJ
Arthritis Rheum; 2013 Jan; 65(1):148-58. PubMed ID: 23044761
[TBL] [Abstract][Full Text] [Related]
18. Critical illness-related bone loss is associated with osteoclastic and angiogenic abnormalities.
Owen HC; Vanhees I; Solie L; Roberts SJ; Wauters A; Luyten FP; Van Cromphaut S; Van den Berghe G
J Bone Miner Res; 2012 Jul; 27(7):1541-52. PubMed ID: 22461003
[TBL] [Abstract][Full Text] [Related]
19. Reduced miR-144-3p expression in serum and bone mediates osteoporosis pathogenesis by targeting RANK.
Wang C; He H; Wang L; Jiang Y; Xu Y
Biochem Cell Biol; 2018 Oct; 96(5):627-635. PubMed ID: 29334613
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement.
Roato I; Grano M; Brunetti G; Colucci S; Mussa A; Bertetto O; Ferracini R
FASEB J; 2005 Feb; 19(2):228-30. PubMed ID: 15550550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
